Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial With Tadekinig Alfa (r-hIL-18BP) in Patients With IL-18 Driven Monogenic Autoinflammatory Conditions: NLRC4 Mutation and XIAP Deficiency

Trial Profile

Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial With Tadekinig Alfa (r-hIL-18BP) in Patients With IL-18 Driven Monogenic Autoinflammatory Conditions: NLRC4 Mutation and XIAP Deficiency

Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Feb 2019

At a glance

  • Drugs Tadekinig alfa (Primary)
  • Indications Autoimmune disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors AB2 Bio
  • Most Recent Events

    • 23 Jan 2019 Planned End Date changed from 1 Dec 2019 to 1 Jul 2020.
    • 23 Jan 2019 Planned primary completion date changed from 1 May 2019 to 1 Nov 2019.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top